FUROSEMIDE (furosemide) by R-Pharm US is clinical pharmacology investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. First approved in 1994.
Drug data last refreshed 11h ago · AI intelligence enriched 14h ago
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the proximal tubule, distal tubule, and loop of Henle, making it one of the most potent diuretics available. It is used to treat fluid overload conditions including edema, congestive heart failure, and hypertension. The drug has a rapid onset (5 minutes IV, slightly longer IM/oral) and peak effect within 30 minutes, with a duration of approximately 2 hours.
As LOE approaches, brand teams are consolidating and focusing on lifecycle extension strategies; commercial headcount typically contracts as generic erosion accelerates.
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption…
Worked on FUROSEMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on furosemide offers stability in a mature, high-volume commodity market but limited growth trajectory. Career development is strongest in cost management, market access, and operational efficiency rather than innovation or product expansion.